News | September 12, 2024
Merck launches single-use reactor to accelerate ADC manufacturing
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Subscribe To Our Newsletter & Stay Updated
